Please login to the form below
pancreatic cancer
This page shows the latest pancreatic cancer news and features for those working in and with pharma, biotech and healthcare.
Celgene’s Abraxane fails pancreatic cancer trial
Since APACT was started, a new regimen called mFOLFIRINOX – based on oxaliplatin, leucovorin, irinotecan, and fluorouracil – has been shown to be more effective gemcitabine in adjuvant pancreatic cancer. ... Celgene also says that there are currently
Latest news
-
CHMP backs Lynparza in breast cancer, Dupixent in asthma
be hoping for further upward momentum, particularly if they can extend the drug’s use even further into pancreatic cancer. ... Pfizer’s Lorviqua (lorlatinib) for the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC); and. -
-
Lynparza scores against pancreatic cancer
AZ and MSD drug success in BRCA-mutated disease. AstraZeneca and partner Merck &Co/MSD may be able to add pancreatic cancer to the list of cancers targeted by PARP inhibitor ... 2-mutated metastatic pancreatic cancer whose disease had not progressed
-
Imbruvica and Gazyvo approved in first non-chemo CLL use
metastatic pancreatic cancer compared to chemo alone.
-
Sanofi and Regeneron re-jig immuno-oncology deal
That candidate is currently in trials for ovarian cancer, but it has potential in cancers expressing the MUC16 biomarker is also frequently expressed in lung, pancreatic, gastric and colorectal cancer.
-
Pfizer gets first FDA nod for hedgehog inhibitor in AML
The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and
More from news
Approximately 22 fully matching, plus 98 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.
-
Finding the patient voice
Mr Whitley took part in a pancreatic cancer drug trial in 2011.
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer,
-
Deal Watch table for September 2014
1. MM-398 a nanoliposomal irinotecan injection of for metastatic pancreatic cancer in phase III. ... 805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for
-
Pharma deals during September 2014
Baxter is licensing Merrimack's nanoliposomal injection of irinotecan which has orphan status in the US and the EU for metastatic pancreatic cancer, but does not have US rights. In contrast,
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Celgene names general manager for UK and Ireland
This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Putting our mission into practice: Porterhouse Medical’s charity round-up 2018 - 2019
The Porterhouse team has also raised funds for Pancreatic Cancer UK (); the ovarian cancer support charity Ovacome (); and the disability sports club SportsAble (). We are delighted to reveal that our team
-
Creative review: ESMO 2018
This year’s theme focused on securing access to optimal cancer care – a poignant topic and one that resonates across the healthcare sector, impacting patients in all walks of life. ... Ipsen Group developed an eye-catching attraction to offset this
-
Porterhouse Medical is raising awareness for pancreatic cancer, here’s why…
44 (0) 118 913 9100. Address:. 4 Windsor Square. Silver Street. Reading. RG1 2TH. United Kingdom.
-
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
5]. In spite of these statistics, funding for pancreatic cancer and disease awareness are low. ... Indeed, in one analysis, only 75% of patients with localised pancreatic cancer underwent surgical evaluation.
-
Porterhouse Medical Group charity round-up for 2017
Other disease awareness and fund-raising activities were carried out throughout the year for World Cancer Day, MPS Awareness Day, Jeans for Genes Day and World Pancreatic Cancer Day.
More from PMHub
Approximately 3 fully matching, plus 4 partially matching documents found.
Featured jobs
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Scientific Director – Medical Communications
-
Salary TBC
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Health Consultant - Brand Comms
-
Competitive Salary
- Senior Account Manager, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
PMHub
Consulting at McCann Health
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
